vs
Apellis Pharmaceuticals, Inc.（APLS）与WARRIOR MET COAL, INC.（HCC）财务数据对比。点击上方公司名可切换其他公司
WARRIOR MET COAL, INC.的季度营收约是Apellis Pharmaceuticals, Inc.的2.3倍（$458.6M vs $199.9M），WARRIOR MET COAL, INC.净利率更高（15.8% vs -29.5%，领先45.3%），WARRIOR MET COAL, INC.同比增速更快（52.1% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 7.5%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Warrior Met Coal（股票代码HCC）是总部位于美国的矿业企业，主营高品质冶金煤的开采与供应，其产品是钢铁制造的核心原材料，主要服务北美、欧洲、亚洲地区的钢铁生产商及工业客户。
APLS vs HCC — 直观对比
营收规模更大
HCC
是对方的2.3倍
$199.9M
营收增速更快
HCC
高出58.0%
-5.9%
净利率更高
HCC
高出45.3%
-29.5%
两年增速更快
APLS
近两年复合增速
7.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $458.6M |
| 净利润 | $-59.0M | $72.3M |
| 毛利率 | — | 36.7% |
| 营业利润率 | -25.6% | 17.3% |
| 净利率 | -29.5% | 15.8% |
| 营收同比 | -5.9% | 52.1% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $1.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSHCC
| Q1 26 | — | $458.6M | ||
| Q4 25 | $199.9M | $384.0M | ||
| Q3 25 | $458.6M | $328.6M | ||
| Q2 25 | $178.5M | $297.5M | ||
| Q1 25 | $166.8M | $299.9M | ||
| Q4 24 | $212.5M | $297.5M | ||
| Q3 24 | $196.8M | $327.7M | ||
| Q2 24 | $199.7M | $396.5M |
净利润APLSHCC
| Q1 26 | — | $72.3M | ||
| Q4 25 | $-59.0M | $23.0M | ||
| Q3 25 | $215.7M | $36.6M | ||
| Q2 25 | $-42.2M | $5.6M | ||
| Q1 25 | $-92.2M | $-8.2M | ||
| Q4 24 | $-36.4M | $1.1M | ||
| Q3 24 | $-57.4M | $41.8M | ||
| Q2 24 | $-37.7M | $70.7M |
毛利率APLSHCC
| Q1 26 | — | 36.7% | ||
| Q4 25 | — | 29.5% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | — | 23.9% | ||
| Q1 25 | — | 18.1% | ||
| Q4 24 | — | 23.1% | ||
| Q3 24 | — | 29.3% | ||
| Q2 24 | — | 34.1% |
营业利润率APLSHCC
| Q1 26 | — | 17.3% | ||
| Q4 25 | -25.6% | 9.0% | ||
| Q3 25 | 48.7% | 6.3% | ||
| Q2 25 | -18.6% | 2.6% | ||
| Q1 25 | -50.0% | -5.8% | ||
| Q4 24 | -12.3% | -1.4% | ||
| Q3 24 | -24.0% | 11.9% | ||
| Q2 24 | -14.7% | 17.9% |
净利率APLSHCC
| Q1 26 | — | 15.8% | ||
| Q4 25 | -29.5% | 6.0% | ||
| Q3 25 | 47.0% | 11.1% | ||
| Q2 25 | -23.6% | 1.9% | ||
| Q1 25 | -55.3% | -2.7% | ||
| Q4 24 | -17.1% | 0.4% | ||
| Q3 24 | -29.2% | 12.7% | ||
| Q2 24 | -18.9% | 17.8% |
每股收益（稀释后）APLSHCC
| Q1 26 | — | $1.37 | ||
| Q4 25 | $-0.40 | $0.43 | ||
| Q3 25 | $1.67 | $0.70 | ||
| Q2 25 | $-0.33 | $0.11 | ||
| Q1 25 | $-0.74 | $-0.16 | ||
| Q4 24 | $-0.30 | $0.02 | ||
| Q3 24 | $-0.46 | $0.80 | ||
| Q2 24 | $-0.30 | $1.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $233.2M |
| 总债务越低越好 | — | $154.4M |
| 股东权益账面价值 | $370.1M | — |
| 总资产 | $1.1B | $2.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSHCC
| Q1 26 | — | $233.2M | ||
| Q4 25 | $466.2M | $300.0M | ||
| Q3 25 | $479.2M | $336.3M | ||
| Q2 25 | $370.0M | $383.3M | ||
| Q1 25 | $358.4M | $454.9M | ||
| Q4 24 | $411.3M | $491.5M | ||
| Q3 24 | $396.9M | $583.2M | ||
| Q2 24 | $360.1M | $709.0M |
总债务APLSHCC
| Q1 26 | — | $154.4M | ||
| Q4 25 | — | $154.3M | ||
| Q3 25 | — | $154.1M | ||
| Q2 25 | — | $153.9M | ||
| Q1 25 | — | $153.8M | ||
| Q4 24 | — | $153.6M | ||
| Q3 24 | — | $153.5M | ||
| Q2 24 | — | $153.3M |
股东权益APLSHCC
| Q1 26 | — | — | ||
| Q4 25 | $370.1M | $2.1B | ||
| Q3 25 | $401.2M | $2.1B | ||
| Q2 25 | $156.3M | $2.1B | ||
| Q1 25 | $164.2M | $2.1B | ||
| Q4 24 | $228.5M | $2.1B | ||
| Q3 24 | $237.1M | $2.1B | ||
| Q2 24 | $264.3M | $2.0B |
总资产APLSHCC
| Q1 26 | — | $2.8B | ||
| Q4 25 | $1.1B | $2.8B | ||
| Q3 25 | $1.1B | $2.7B | ||
| Q2 25 | $821.4M | $2.6B | ||
| Q1 25 | $807.3M | $2.6B | ||
| Q4 24 | $885.1M | $2.6B | ||
| Q3 24 | $901.9M | $2.6B | ||
| Q2 24 | $904.5M | $2.6B |
负债/权益比APLSHCC
| Q1 26 | — | — | ||
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 0.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSHCC
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $76.1M | ||
| Q3 25 | $108.5M | $104.7M | ||
| Q2 25 | $4.4M | $37.5M | ||
| Q1 25 | $-53.4M | $10.9M | ||
| Q4 24 | $19.4M | $54.2M | ||
| Q3 24 | $34.1M | $62.2M | ||
| Q2 24 | $-8.3M | $147.0M |
自由现金流APLSHCC
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — |
自由现金流率APLSHCC
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — |
资本支出强度APLSHCC
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — |
现金转化率APLSHCC
| Q1 26 | — | — | ||
| Q4 25 | — | 3.31× | ||
| Q3 25 | 0.50× | 2.86× | ||
| Q2 25 | — | 6.70× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 47.68× | ||
| Q3 24 | — | 1.49× | ||
| Q2 24 | — | 2.08× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
HCC
| Sales | $448.5M | 98% |
| Other revenues | $10.1M | 2% |
